A way forward for cancer prevention therapy: Personalized risk assessment

Zhenzhen Zhang, Jeffrey Bien, Motomi Mori, Sonali Jindal, Raymond Bergan

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Cancer is characterized by genetic and molecular aberrations whose number and complexity increase dramatically as cells progress along the spectrum of carcinogenesis. The pharmacologic application of agents in the context of a lower burden of dysregulated cellular processes constitutes an efficient strategy to enhance therapeutic efficacy, and underlies the rationale for using cancer prevention agents in high-risk populations. A longstanding barrier to implementing this strategy is that the risk in the general population is low for any given cancer, many people would have to be treated in order to benefit a few. Therefore, identifying and treating high-risk individuals will improve the risk: benefit ratio. Currently, risk is defined by considering a relatively low number of factors. A strategy that considers multiple factors has the ability to define a much-higher-risk cohort than the general population. This article will review the rationale for evaluating multiple risk factors so as to identify individuals at highest risk. It will use breast and lung cancer as examples, will describe currently available risk assessment tools, and will discuss ongoing efforts to expand the impact of this approach. The high potential of this strategy to provide a way forward for developing cancer prevention therapy will be highlighted.

Original languageEnglish (US)
Pages (from-to)6898-6912
Number of pages15
Issue number64
StatePublished - 2019


  • Cancer
  • Multiple risk factors
  • Prevention
  • Prevention therapy
  • Screening

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'A way forward for cancer prevention therapy: Personalized risk assessment'. Together they form a unique fingerprint.

Cite this